Braunstein, L. Z., Mitchell, M. P., Bandos, H., Sikov, W. M., Khan, A. J., Chen, P. Y., Ganz, P. A., Jagsi, R., White, J. R., Cecchini, R. S., Kang, H., Puhalla, S. L., Bolton, K. L., Connolly, E. P., Stringer-Reasor, E. M., Gergelis, K. R., Julian, T. B., Mamounas, E. P., & Wolmark, N. (2025). NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncology, 1–9. https://doi.org/10.1080/14796694.2025.2511586

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncology, 20(12), 717–726. https://doi.org/10.2217/fon-2023-0849

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249

Shelbaya, A., Kelton, J. M., Thompson, J., Alvir, J. M., Maculaitis, M. C., & Yang, J. (2021). Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA. Future Oncology, 17(30), 3941–3950. https://doi.org/10.2217/fon-2021-0618